Sonoma Pharmaceuticals, Inc. (SNOA) financial statements and ratios from SEC XBRL: revenue $19.53M (TTM), net margin -16.3%, revenue growth 36.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $19.53M |
| Net Margin | -16.3% |
| Return on Equity | -34.3% |
| Debt / Equity | 0.02 |
| Current Ratio | 2.99 |
| Revenue Growth (YoY) | 36.7% |
| EPS Growth (YoY) | -32.3% |
| FCF Growth (YoY) | 2355.4% |
| Price / Book | 0.35 |
| Price / Sales | 0.11 |
| FCF Yield | -390.1% |
| Altman Z-Score | -18.36 (distress) |
| Piotroski F-Score | 3/9 |
| Sector P/E (Healthcare) | 21.6 |
SNOA overview · SNOA earnings · SNOA KPIs · SNOA investor relations · SNOA ownership · SNOA peers · SNOA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.